Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioMarin Pharmaceutical Inc. or Biogen Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how BioMarin Pharmaceutical Inc. and Biogen Inc. compare based on key financial metrics to determine which better meets your investment needs.

About BioMarin Pharmaceutical Inc. and Biogen Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and BioMarin Pharmaceutical Inc., Biogen Inc. Stock News

As of September 2, 2026, BioMarin Pharmaceutical Inc. had a $13.0 billion market capitalization, compared to the Biotechnology median of $288.9 million. BioMarin Pharmaceutical Inc.’s stock is up 12.7% in 2026, up 2.1% in the previous five trading days and up 13.34% in the past year.

Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 176.7. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.4 billion with a 2.1% net profit margin. Year-over-year quarterly sales growth most recently was 19.9%. Analysts expect adjusted earnings to reach $5.030 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

As of September 2, 2026, Biogen Inc. had a $32.9 billion market cap, putting it in the 90th percentile of all stocks. Biogen Inc.’s stock is up 26.5% in 2026, up 0.7% in the previous five trading days and up 59.47% in the past year.

Currently, Biogen Inc.’s price-earnings ratio is 39.5. Biogen Inc.’s trailing 12-month revenue is $10.0 billion with a 8.3% net profit margin. Year-over-year quarterly sales growth most recently was 3.4%. Analysts expect adjusted earnings to reach $12.412 per share for the current fiscal year. Biogen Inc. does not currently pay a dividend.

How We Compare BioMarin Pharmaceutical Inc. and Biogen Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioMarin Pharmaceutical Inc. and Biogen Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

BioMarin Pharmaceutical Inc. and Biogen Inc. Growth Grades

Company	Ticker	Growth
BioMarin Pharmaceutical Inc.	BMRN	A
Biogen Inc.	BIIB	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

BioMarin Pharmaceutical Inc. has a Growth Score of 82, which is Very Strong. Biogen Inc. has a Growth Score of 16, which is Very Weak.

The Growth Grade Winner: BioMarin Pharmaceutical Inc.

As you can clearly see from the Growth Grade breakdown above, BioMarin Pharmaceutical Inc. has a more attractive growth grade than Biogen Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, BioMarin Pharmaceutical Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioMarin Pharmaceutical Inc. and Biogen Inc.’s Momentum Grades

Company	Ticker	Momentum
BioMarin Pharmaceutical Inc.	BMRN	B
Biogen Inc.	BIIB	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

BioMarin Pharmaceutical Inc. has a Momentum Score of 65, which is Strong. Biogen Inc. has a Momentum Score of 79, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both BioMarin Pharmaceutical Inc. and Biogen Inc. have a grade of B. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

BioMarin Pharmaceutical Inc. and Biogen Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
BioMarin Pharmaceutical Inc.	BMRN	C
Biogen Inc.	BIIB	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

BioMarin Pharmaceutical Inc. has a Earnings Estimate Score of 52, which is Neutral. Biogen Inc. has a Earnings Estimate Score of 34, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither BioMarin Pharmaceutical Inc. or Biogen Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if BioMarin Pharmaceutical Inc. or Biogen Inc. is the better investment when it comes to estimate revisions.

Other BioMarin Pharmaceutical Inc. and Biogen Inc. Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether BioMarin Pharmaceutical Inc. and Biogen Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, BioMarin Pharmaceutical Inc. or Biogen Inc. Stock?

Overall, BioMarin Pharmaceutical Inc. stock has a Growth Score of 82, Momentum Score of 65 and Estimate Revisions Score of 52.

Biogen Inc. stock has a Growth Score of 16, Momentum Score of 79 and Estimate Revisions Score of 34.

Comparing BioMarin Pharmaceutical Inc. and Biogen Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.